RhumbLine Advisers’s BioLineRX BLRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.5K | Buy |
4,275
+2,745
| +179% | +$12.5K | ﹤0.01% | 3797 |
|
|
2025
Q1 | $4.52K | Buy |
1,530
+456
| +42% | +$1.35K | ﹤0.01% | 3918 |
|
|
2024
Q4 | $9.15K | Buy |
1,074
+259
| +32% | +$2.21K | ﹤0.01% | 3894 |
|
|
2024
Q3 | $17.5K | Buy |
815
+171
| +27% | +$3.67K | ﹤0.01% | 3829 |
|
|
2024
Q2 | $14.6K | Buy |
644
+186
| +41% | +$4.21K | ﹤0.01% | 3918 |
|
|
2024
Q1 | $20.5K | Sell |
458
-12
| -3% | -$538 | ﹤0.01% | 3757 |
|
|
2023
Q4 | $29.5K | Buy |
470
+86
| +22% | +$5.4K | ﹤0.01% | 3718 |
|
|
2023
Q3 | $27.9K | Buy |
384
+44
| +13% | +$3.2K | ﹤0.01% | 3732 |
|
|
2023
Q2 | $21.7K | Buy |
+340
| New | +$21.7K | ﹤0.01% | 3803 |
|
|
2022
Q4 | – | Sell |
-427
| Closed | -$16K | – | 3005 |
|
|
2022
Q3 | $16K | Buy |
427
+63
| +17% | +$2.36K | ﹤0.01% | 3069 |
|
|
2022
Q2 | $19K | Hold |
364
| – | – | ﹤0.01% | 3080 |
|
|
2022
Q1 | $25K | Hold |
364
| – | – | ﹤0.01% | 2999 |
|
|
2021
Q4 | $30K | Hold |
364
| – | – | ﹤0.01% | 2996 |
|
|
2021
Q3 | $40K | Buy |
364
+22
| +6% | +$2.42K | ﹤0.01% | 3026 |
|
|
2021
Q2 | $38K | Hold |
342
| – | – | ﹤0.01% | 2978 |
|
|
2021
Q1 | $38K | Sell |
342
-13
| -4% | -$1.44K | ﹤0.01% | 2980 |
|
|
2020
Q4 | $36K | Buy |
+355
| New | +$36K | ﹤0.01% | 3029 |
|
|
2019
Q3 | – | Sell |
-21
| Closed | -$5K | – | 2950 |
|
|
2019
Q2 | $5K | Hold |
21
| – | – | ﹤0.01% | 2965 |
|
|
2019
Q1 | $5K | Sell |
21
-10
| -32% | -$2.38K | ﹤0.01% | 2940 |
|
|
2018
Q4 | $8K | Hold |
31
| – | – | ﹤0.01% | 2973 |
|
|
2018
Q3 | $20K | Buy |
+31
| New | +$20K | ﹤0.01% | 2917 |
|